Patents Assigned to Korea Research Institute of Bioscience & Biotechnology
  • Publication number: 20240008460
    Abstract: The present disclosure relates to a JAK3 gene-mutated severe combined immunodeficiency animal model and a method of constructing the same. In the JAK3 gene-mutated severe combined immunodeficiency animal model of the present disclosure, the JAK3 gene is specifically deficient, the expression of cytokines is regulated by controlling the number and activity of macrophages, and the thymus, lymphocytes, and Peyer's patches, which are observed in conventional severe combined immunodeficiency animal models, particularly mini-pigs, are completely lacking. In addition, the animal model of the present disclosure can be used as a treatment model for JAK3 SCID patients, as similar phenotypes are observed in patients with human severe combined immunodeficiency caused by a JAK3 gene mutation, and can be used for artificial blood development or xenotransplantation.
    Type: Application
    Filed: October 15, 2021
    Publication date: January 11, 2024
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Sun Uk KIM, Young Ho PARK, Bo Woong SIM, Kyu Tae CHANG, Seung Hwan LEE, Bong Seok SONG, Pil Soo JEONG, Hae Jun YANG, Sang Rae LEE, Yeung Bae JIN, Kang Jin JEONG
  • Publication number: 20240002934
    Abstract: The present invention relates to a technology for analyzing and detecting/diagnosing a target nucleic acid. When the detection system according to the present invention is used, effective real-time detection or diagnosis efficiency can be obtained while problems such as noise are minimized. In particular, since, by using a house-keeping gene according to a method of use, the expression difference of the target nucleic acid can be corrected, and direct real-time target nucleic acid detection is possible, it can be effectively used for detecting various nucleic acids and diagnosing various diseases thereby.
    Type: Application
    Filed: November 3, 2021
    Publication date: January 4, 2024
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Eun Kyung LIM, Jae Woo LIM, Byung Hoon KANG, Tae Joon KANG, Seung Beom SEO, Soo Jin JANG, Ju Yeon JUNG
  • Publication number: 20230364170
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating obesity or diabetes, and to a food composition and feed composition for preventing or alleviating obesity or diabetes, comprising as an active ingredient, an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. The composition has synergistic antidiabetic and antiobesity activity compared to that of using only an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. Therefore, it is possible to reduce the possibility of any side effects that may be caused by an overdose of or long-term administration of the garcinia cambogia extract and a substance isolated therefrom, and thus the composition can be very effectively utilized in the development of a therapeutic agent for diabetes or obesity.
    Type: Application
    Filed: August 18, 2021
    Publication date: November 16, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Su Ui LEE, Hyung Won RYU, Mun Ock KIM, Sei Ryang OH, Doo Young KIM, Hyun Jae JANG
  • Patent number: 11814661
    Abstract: The present invention relates to a method for producing a dimeric stilbene using a plant callus culture solution. More specifically, the present invention relates to a method for producing a dimeric stilbene using a plant callus culture solution and a composition for dimeric stilbene production, which contains a plant callus culture solution as an active ingredient.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: November 14, 2023
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Cha Young Kim, Suhyun Park, Yu Jeong Jeong, Jae Cheol Jeong, Young Bae Ryu, Suk Weon Kim, Jiyoung Lee, Sung-Chul Park
  • Publication number: 20230348917
    Abstract: Disclosed are a vector comprising a first expression cassette comprising a DmpR ribosomal binding site as a transcriptional regulator and a promoter operably linked thereto; and a second expression cassette comprising a sequence encoding a target polypeptide, a ribosomal binding site, and a Po promoter operably linked thereto, and a methanotroph transformed by the vector.
    Type: Application
    Filed: March 24, 2023
    Publication date: November 2, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Seung Goo LEE, Dae Hee Lee, Hye Won Lee, Seong Keun Kim, Ji In Baek, Tae Hyun Kim, So Hyung Oh
  • Publication number: 20230333109
    Abstract: The present invention relates to a composition for diagnosing infectious diseases, comprising an agent for measuring the expression level of sterol regulatory element-binding protein 2 (SREBP2) and, more specifically, to a composition for diagnosing infectious diseases or diagnosing the severity thereof, the composition comprising an agent for measuring the expression level of sterol regulatory element-binding protein 2 (SREBP2) or a C-terminal peptide thereof.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 19, 2023
    Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Young Kyo SEO, Jong Sup BAE, Wonhwa LEE, Youngbum YOO
  • Publication number: 20230303965
    Abstract: The present invention relates to a novel Lactobacillus reuteri DS0384 strain and the use of thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: September 28, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Mi-Young SON, Doo-Sang PARK, Kwang Bo JUNG, Hana LEE
  • Publication number: 20230304989
    Abstract: The disclosure relates to nanopore-based technology for screening of drugs against target RNA. According to the screening method of the disclosure, drugs targeting RNA can be efficiently screened even with a very small amount sample of picomolar concentration. The discovered drugs targeting RNA can be used in the treatment of diseases associated with RNAs.
    Type: Application
    Filed: March 28, 2023
    Publication date: September 28, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Seung-Wook CHI, Mi-Kyung Lee, Donghwa Lee, Sohee Oh
  • Publication number: 20230305028
    Abstract: The present disclosure provides a reagent composition for detecting illicit drugs, the composition comprising: a diacetylene derivative compound represented by chemical formula 1; and at least one compound selected from among gabazine (SR-95531), an amine group-linked diacetylene derivative represented by chemical formula 2-1, and a gabazine-linked diacetylene derivative represented by chemical formula 2-2.
    Type: Application
    Filed: May 14, 2021
    Publication date: September 28, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Eun Kyung LIM, Soo Jin JANG, Seong Uk SON, Byung Hoon KANG, Tae Joon KANG, Kyu Sun LEE, Ju Yeon JUNG
  • Patent number: 11738063
    Abstract: The present invention relates to a pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases which include a flower extract of Daphne genkwa or fractions thereof as an active ingredient. The pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases are, not like extracts from stems and/or roots of Daphne genkwa, free from genotoxicity and have superior prophylactic or treatment effects against neurodegenerative diseases.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 29, 2023
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Won Gon Kim, Baek Soo Han, Jeong Su Byun, Ha Young Choi
  • Patent number: 11732232
    Abstract: The present disclosure provides a biomimetic cell culture apparatus that mimics interactions among organs in a human body. The present disclosure includes a plurality of culture units for culturing cells, a conduit for connecting the plurality of culture units to each other to form a circulating path, a pump unit disposed on the conduit for forming a flow in culture medium such that the culture medium circulates through the plurality of culture units, and an agitating module for agitating the plurality of culture units.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: August 22, 2023
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Cho Rok Jung, Jung Hwa Lim, Hyun Mi Kang, Kyung Hee Noh, Kyung Sook Chung, Mi Young Son, Myung Jin Son
  • Publication number: 20230235382
    Abstract: The present invention provides a target RNA detection method based on a dCas9/gRNA complex. A target RNA detection method according to the present invention can detect target RNA with the naked eye and without separate gene isolation and amplification steps, and, in particular, can rapidly and accurately detect target RNA through excellent target specificity and rapidity, and thus can exhibit excellent effects on the detection of various pathogens and/or viruses.
    Type: Application
    Filed: February 3, 2023
    Publication date: July 27, 2023
    Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, BIONANO HEALTH GUARD RESEARCH CENTER
    Inventors: Tae Joon KANG, Jeong Moon, Ju Yeon Jung, Kyu Sun Lee, Eun Kyung Lim, Hong Ki Kim, Hyun Ju Kang
  • Patent number: 11707486
    Abstract: Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: July 25, 2023
    Assignees: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: In Pyo Choi, Tae-Don Kim, Su Ui Lee, Sooyun Lee, Junho Chung, Ki-Hyun Kim, Hyori Kim
  • Publication number: 20230190856
    Abstract: The present disclosure relates to a composition comprising a complex that includes a curcuminoid-based compound and a steviol glycoside, or a curcuminoid-based compound and a licorice extract or a fraction thereof; and a use of the composition for enhancement of immunity according to an enhancement of activity or a cell number of immune cells and/or a use of the composition for prevention, improvement, or treatment of COVID-19. The complex including curcumin and a steviol glycoside, or a licorice extract or a fraction thereof according to the present disclosure, which are food materials that have been registered with the Ministry of Food and Drug Safety and have received the Generally Recognized as Safe (GRAS) rating from the U.S. FDA, and whose safety has already been confirmed, inhibits symptoms of COVID-19 by activating Th1 cells, CD8 T cells, and NK cells. Therefore, the complex can be provided as a food and pharmaceutical composition for preventing, improving, or treating COVID-19.
    Type: Application
    Filed: December 19, 2022
    Publication date: June 22, 2023
    Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, BIOTEN CO., LTD
    Inventors: Woo Song LEE, Hyung-Jun Kwon, Woo Sik Kim, Young Bae Ryu, In Chul Lee, Hyung Jae Jeong, Ji Young Park
  • Patent number: 11474093
    Abstract: The present invention relates to a method for screening protein-protein interaction inhibitors using a nanopore, a method for analyzing protein structures, a method for analyzing protein-protein interactions, and a kit therefor.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: October 18, 2022
    Assignees: Korea Research Institute of Bioscience and Biotechnology, Seoul National University R&DB Foundation
    Inventors: Seung Wook Chi, Ki Bum Kim, Dong Kyu Kwak, Mi Kyung Lee, Hong Sik Chae, Ji Hyang Ha
  • Patent number: 11464787
    Abstract: The present invention relates to a composition for preventing, improving or treating drug-induced nephrotoxicity, the composition comprising oleanolic acid acetate as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating drug-induced nephrotoxicity comprising oleanolic acid acetate or a pharmaceutically acceptable salt thereof as an active ingredient, a health functional food for preventing or improving drug-induced nephrotoxicity comprising the active ingredients, and an anticancer adjuvant comprising the active ingredients. The oleanolic acid acetate of the present invention is derived from a natural product and has no side effects and no cytotoxicity and has excellent effects of preventing, improving and treating nephrotoxicity caused by a drug, particularly a platinum-based anticancer drug, so that it can be utilized as a pharmaceutical composition, a health functional food, and a cancer adjuvant thereof.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 11, 2022
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Mun Chual Rho, Seung Woong Lee, Soyoung Lee, Sang-Hyun Kim, Kwon Moo Park, Woo Song Lee, Kyungsook Jung, Chan Sun Park
  • Patent number: 11446281
    Abstract: The present invention relates to a composition for preventing, alleviating or treating inflammatory diseases, comprising, as an active ingredient, an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of the present invention, effectively inhibits inflammatory cytokines and inflammatory signaling pathways, thereby effectively alleviating symptoms of inflammatory diseases such as dermatitis. Therefore, the composition according to the present invention may be effectively used for the prevention, alleviation or treatment of inflammatory diseases.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 20, 2022
    Assignee: Korea Research Institute Of Bioscience And Biotechnology
    Inventors: Bo Yeon Kim, Joonsung Hwang, Nak Kyun Soung, Jong Seog Ahn, Kyung Ho Lee, Jiyun Mun, Srinivasrao Ganipisetti, Hyunjoo Cha, Mija Ahn, Hee Gu Lee, Jae-Hyuk Jang, In Ja Ryoo, Sung-Kyun Ko
  • Publication number: 20220213556
    Abstract: A method for analyzing the methylation level of a specific CpG site in genomic DNA and a composition suitable to use in the method are provided. The method and composition can provide information useful for diagnosing thyroid cancer or determining the prognosis of patients with thyroid cancer. By using the method and the composition, thyroid cancer can be easily and accurately diagnosed from biological samples at a low cost.
    Type: Application
    Filed: March 26, 2020
    Publication date: July 7, 2022
    Applicants: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Chan Kwon JUNG, Yong Sung KIM, Jong Lyul PARK
  • Publication number: 20220184128
    Abstract: The present invention relates to a method for producing induced natural killer (iNK) cells, into which a chimeric antigen receptor (CAR) gene encoding a CAR is introduced, iNK cells produced by the method, and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNK cells. The method according to the present invention has the effects of producing the iNK cells, into which a CAR gene is introduced, with high efficiency through direct reprogramming from isolated cells without limiting an initial cell, and directly producing the same without a differentiation process, thereby simplifying the production process and reducing costs and time. The method according to the present invention has the effect of producing excellent NK cells having enhanced safety by directly producing NK cells from human somatic cells that are easy to obtain, without passing through induced pluripotent stem cells produced through conventional reprogramming technology.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Yee Sook CHO, Han-Seop KIM, Jae Yun KIM, Binna SEOL
  • Publication number: 20220160769
    Abstract: The present invention relates to: a method for producing immunocytes, specifically induced natural killer T (iNKT) cells that are induced by direct reprogramming of isolated somatic cells, and chimeric antigen receptor (CAR)-iNKT cells into which a CAR gene encoding a CAR is introduced; iNKT cells produced by the method; and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNKT cells. The method according to the present invention can produce, through direct reprogramming, iNKT cells or iNKT cells into which a CAR gene is introduced, from isolated cells so as to simplify the production process and shorten production time, thereby reducing costs, to have excellent NKT cell production efficiency, and to ensure safety according to the production without passing through induced pluripotent stem cells, thereby having an excellent NKT cell production effect distinguished from that of a conventional reprogramming technique.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 26, 2022
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Yee Sook CHO, Han-Seop KIM, Jae Yun KIM, Binna SEOL